Published on 21 May 2024
Description:
Welcome to the spring 2024 issue of Pharmafile! This issue includes the biggest pharma news, as well as fascinating articles on women's health, rare diseases, and psychoactives!
26 articles from this collection:
Pharmafile spring 2024
Welcome to the spring 2024 issue of Pharmafile! This issue includes the biggest pharma news, as well as fascinating articles on women's health, rare diseases, and psychoactives!
FLYPHARMA VIENNA 2024
Www.flypharmaeurope.com
Contents
Welcome to the spring 2024 issue of Pharmafile! This issue includes the biggest pharma news, as well as fascinating articles on women's health, rare diseases, and psychoactives!
Comment
Welcome to the spring 2024 issue of Pharmafile! As the weather starts to warm up and spring is finally upon us, the themes of change, growth and rejuvenation are at the forefront of our minds, therefore now seems like the perfect time to consider these themes within the pharma industry.
Pharmafocus
Www.pharmafocus.com
FDA approves Pfizer’s Beqvez for haemophilia B treatment
Pfizer has announced that the FDA has approved Beqvez (fidanacogene elaparvovec-dzkt) for the treatment of adults with moderate-to-severe haemophilia b.
CHMP grants positive opinion for J&J’s Rybrevant for lung cancer treatment
Janssen, a J&J company, has announced that the CHMP of the EMA has recommended Rybrevant (amivantamab) in combination with chemotherapy.
MHRA approves Ascendis Pharma’s Yorvipath for hypoparathyroidism treatment
Ascendis Pharma has announced that the MHRA has granted marketing authorisation for yorvipath (palopegteriparatide; developed as transcon pth) in GB as a parathyroid hormone (pth) replacement therapy for the treatment of adult patients with chronic hypoparathyroidism.
FDA approves Roche’s Alecensa as lung cancer treatment
Roche has announced that the FDA has approved Alecensa (alectinib) for the adjuvant treatment following tumour resection for patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC).
FDA to review GSK’s meningococcal vaccine candidate
GSK has announced that the FDA has accepted for review a biologics license application (BLA) for its 5-in-1 meningococcal abcwy (menabcwy) vaccine candidate.
Eko Health’s AI for heart failure detection approved by FDA
Eko Health has announced that the FDA has approved its low ejection fraction (low EF) detection artificial intelligence (AI).
ANGLE and AstraZeneca sign commercial agreement
ANGLE has announced that it has signed a supplier agreement with AstraZeneca for the development and validation of a methodology that will leverage angle’s existing DNA damage response (DDR) assay for the detection of micronuclei in circulating tumour cells (CTCs) as a measure of DDR.
Regeneron and Mammoth Biosciences to collaborate on CRISPR gene therapies
Regeneron Pharmaceuticals and Mammoth Biosciences have announced a collaboration for the research, development and commercialisation of in vivo CRISPR-based gene-editing therapies for multiple tissue and cell types.
Addressing orphan, rare and paediatric drug development through collaborative partnerships
Nazim Kanji and Huw Jones from Quotient Sciences consider orphan drug development and the benefit of CRO/CDMO collaboration, specifically in terms of paediatric rare diseases
YOURWAY
Www.yourway.com
Reimagining the clinical trial paradigm for rare disease patients
Elizabeth Sachnoff from Propharma considers the landscape of clinical trials for rare diseases, and how these could be improved
Overcoming obstacles in rare disease treatment
Dan Williams from SynaptixBio considers the problems facing the ongoing treatment of rare diseases, as well as how the pharma industry is moving forwards in their treatment
Transforming access: the power of patient-centricity in rare disease
Dana Vigier from Alexion considers the challenges facing rare disease treatment and the importance of patient-centricity to improve outcomes
Advancing treatment options for rare disease patients
Chris Moore from Veeva Europe explores how companies are overcoming challenges to develop, launch and educate on new rare disease medicines faster
Psychoactives in mental health treatment
Kabir Nath from Compass Pathways explores the need for new treatments in the mental health space, as well as assessing whether psychoactives could be the way forward
Psychedelic medicines and the treatment of neurological conditions
Rob Conley from Beckley Psytech tells Pharmafile about the use of psychedelic medicine for the treatment of psychiatric and neurological conditions, and how this field could develop in the future
SAMEDAN
Www.samedanltd.com
Reducing unintended pregnancy rates: how innovation in contraception can drive generational change
Dr Charlotte Owens from Organon explores the impact of innovations in contraception and how this can reduce unintended pregnancy rates
International Women’s Day remains a key platform to keep inspiring inclusive, innovative healthcare
Frances Ramsay from InnoScot Health discusses the way forward in closing the gender health gap
Events
Don't miss the biggest upcoming events in the world of pharma.
PMPS - SAMEDAN
Www.samedanltd.com
Pharmafile
Therapeutic areas in focus